CEO commentaries

To transform an invention to a product that can be purchased by any scientist is the often unappreciated but crucial role of commercializing enterprises. This was the underlying theme of my presentation at SPIE 2018, “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”.

In our daily lives, we all know how important it is to plan ahead to avoid a future mess. Ironically, we ourselves are such a future mess.

Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.

Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.

Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.